|
|
 |
|
Action Agenda |
|
|
 |
|
|
The Action Agenda is the six- to eight-year blueprint to transform Schering-Plough into a global, high-performance competitor for the long term. It is anchored on the principles of "new thinking, new capabilities and new urgency" -- the drivers of continuous renewal and reinvention.
Schering-Plough's Action Agenda, which was launched in 2003, is a six- to eight-year plan with five phases: Stabilize, Repair, Turnaround, Build the Base and Breakout. The first three phases are complete, and the company is now in the Build the Base phase. We are building the breadth and depth of our capabilities and extending our strength to new patients, new customers and new markets.
When the Action Agenda's fourth phase is completed, the company will enter the final part of its transformational journey. During Breakout, Schering-Plough will achieve continued superior performance and leadership in the pharmaceutical industry.
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
